| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Erasca Inc. Common Stock (NASDAQ: ERAS)
ERAS Technical Analysis
5
| As on 9th Jun 2023 ERAS STOCK Price closed @ 2.95 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 8.88 & Strong Sell for SHORT-TERM with Stoploss of 12.64 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ERASSTOCK Price
| Open | 2.89 | Change | Price | % |
| High | 3.05 | 1 Day | 0.23 | 8.46 |
| Low | 2.87 | 1 Week | 0.14 | 4.98 |
| Close | 2.95 | 1 Month | 0.35 | 13.46 |
| Volume | 892600 | 1 Year | -10.70 | -78.39 |
| 52 Week High 15.58 | 52 Week Low 2.57 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ERAS Daily Charts |
ERAS Intraday Charts |
Whats New @ Bazaartrend |
ERAS Free Analysis |
|
|
ERAS Important Levels Intraday
| RESISTANCE | 3.30 |
| RESISTANCE | 3.19 |
| RESISTANCE | 3.12 |
| RESISTANCE | 3.05 |
| SUPPORT | 2.85 |
| SUPPORT | 2.78 |
| SUPPORT | 2.71 |
| SUPPORT | 2.60 |
ERAS Forecast May 2024
| 4th UP Forecast | 12.84 |
| 3rd UP Forecast | 9.67 |
| 2nd UP Forecast | 7.71 |
| 1st UP Forecast | 5.75 |
| 1st DOWN Forecast | 0.15 |
| 2nd DOWN Forecast | -1.81 |
| 3rd DOWN Forecast | -3.77 |
| 4th DOWN Forecast | -6.94 |
ERAS Weekly Forecast
| 4th UP Forecast | 8.08 |
| 3rd UP Forecast | 6.43 |
| 2nd UP Forecast | 5.42 |
| 1st UP Forecast | 4.40 |
| 1st DOWN Forecast | 1.50 |
| 2nd DOWN Forecast | 0.48 |
| 3rd DOWN Forecast | -0.53 |
| 4th DOWN Forecast | -2.18 |
ERAS Forecast2024
| 4th UP Forecast | 28.98 |
| 3rd UP Forecast | 20.63 |
| 2nd UP Forecast | 15.47 |
| 1st UP Forecast | 10.31 |
| 1st DOWN Forecast | -4.41 |
| 2nd DOWN Forecast | -9.57 |
| 3rd DOWN Forecast | -14.73 |
| 4th DOWN Forecast | -23.08 |
Erasca Inc. Common Stock ( NASDAQ USA Symbol : ERAS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ERAS Business Profile
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California. Address: 10835 Road to the Cure, San Diego, CA, United States, 92121
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service